Leaflet SANDOSTATIN LAR 30mg powder+solvent for suspension injection (intramuscular) with prolonged release


Indicated for: acromegaly; neuroendocrine tumors

Substance: octreotide (somatostatin analogue)

ATC: H01CB02 (Systemic hormonal preparations, excluding sex hormones and insulins | Hypothalamic hormones | Somatostatin and analogues)

Octreotide is a synthetic analog of somatostatin used for the treatment of acromegaly, neuroendocrine tumors, and other conditions associated with hormonal hypersecretion. It works by inhibiting the release of hormones such as growth hormone, insulin, and glucagon.

The medication is administered as subcutaneous or intramuscular injections, as directed by a doctor. The dosage and frequency of administration are adjusted based on the patient's response to treatment.

Patients should be monitored for potential side effects, such as nausea, diarrhea, or pain at the injection site. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, diarrhea, abdominal pain, and pain at the injection site. In rare cases, severe reactions such as hyperglycemia or cholelithiasis may occur. Patients should be informed of these risks before starting treatment.

General data about SANDOSTATIN LAR 30mg

  • Substance: octreotide
  • Date of last drug list: 01-01-2019
  • Commercial code: W42956001
  • Concentration: 30mg
  • Pharmaceutical form: powder+solvent for suspension injection (intramuscular) with prolonged release
  • Quantity: 1
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: NOVARTIS PHARMA GMBH - GERMANIA
  • Holder: NOVARTIS PHARMA GMBH - GERMANIA
  • Number: 6871/2014/01
  • Shelf life: 3 years

Concentrations available for octreotide

  • 0.1mg/ml
  • 100mcg/ml
  • 10mg
  • 20mg
  • 30mg
  • 500mcg/ml
  • 50mcg/ml